文献速递糖尿病

2型糖尿病伴氯沙坦抵抗性大量白蛋白尿患者中适度限盐联合或不联合帕立骨化醇(PROCEED):随机双盲安慰剂对照交叉试验

Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-11-02

在意大利北部六家糖尿病门诊招募的2型糖尿病伴大量白蛋白尿患者中,低钠饮食(每日钠摄入减少30 mEq,约相当于每日1.7-1.8克)使24小时白蛋白尿降低36.6%(95%CI 28.5-44.9),而高钠饮食组无显著变化。高钠饮食下帕立骨化醇较低钠饮食下更显著降低盐诱导的白蛋白尿增加17.8%(95%CI 3.9-32.3),低钠饮食下帕立骨化醇与安慰剂无显著差异。

要点

  • 低钠饮食(每日钠摄入减少30 mEq,约相当于每日1.7-1.8克)使24小时白蛋白尿降低36.6%(95%CI 28.5-44.9)。
  • 高钠饮食下帕立骨化醇较低钠饮食下更显著降低盐诱导的白蛋白尿增加17.8%(95%CI 3.9-32.3)。
  • 低钠饮食下帕立骨化醇与安慰剂相比白蛋白尿无显著变化(增加4.1%,95%CI -9.3至21.6)。

核心结论

  • 在2型糖尿病伴大量白蛋白尿患者中,适度限盐增强氯沙坦的降白蛋白尿效应,该效应长期可能具有肾脏和心脏保护作用。
  • 帕立骨化醇可预防钠诱导的白蛋白尿增加,为在2型糖尿病伴大量白蛋白尿且对饮食限盐(包括甚至适度限盐)难治的患者中测试帕立骨化醇附加治疗的长期风险-获益特征提供了支持。

研究设计与样本

  • 随机、双盲、安慰剂对照、交叉试验,从意大利北部六家糖尿病门诊招募成人2型糖尿病患者。
  • 纳入标准包括:每日100 mg氯沙坦治疗下24小时白蛋白尿>300 mg、血压<140/90 mm Hg、血清肌酐<2 mg/dL、稳定肾素-血管紧张素系统抑制剂治疗且氯沙坦剂量固定、甲状旁腺激素20 pg/mL至<110 pg/mL、血清钙<9.5 mg/dL、血清磷<5 mg/dL,且1个月安慰剂导入期依从性>80%。
  • 采用计算机生成随机化按1:1分配至开放标签3个月高钠饮食(>200 mEq[4.8 g]/天)或低钠饮食(<100 mEq[2.4 g]/天),每个饮食组内再分配至1个月双盲口服帕立骨化醇(2 μg/天)或安慰剂,随后1个月安慰剂洗脱,再交叉至相反治疗1个月。
  • 主要结局为24小时白蛋白尿(三次连续测量的中位数),分析采用改良意向治疗(包括所有随机分配、至少接受一剂研究药物且第一治疗期后有疗效测量的患者)。
  • 2011年12月13日至2015年2月17日期间,57例(50%)分配至低钠饮食(28例[49%]先帕立骨化醇后安慰剂,29例[51%]先安慰剂后帕立骨化醇),58例(50%)分配至高钠饮食(29例[50%]先帕立骨化醇后安慰剂,29例[50%]先安慰剂后帕立骨化醇)。

主要发现

  • 低钠饮食组(每日钠摄入减少30 mEq,约相当于每日1.7-1.8克)24小时白蛋白尿从基线724 mg(441-1233)降至第3个月481 mg(289-837),降低36.6%(95%CI 28.5-44.9;p<0.0001)。
  • 高钠饮食组24小时白蛋白尿从730 mg(416-1227)至801 mg(441-1365),增加2.9%(95%CI -16.8至16.4;p=0.50),无显著变化。
  • 饮食组间变化差异为32.4%(95%CI 17.2-48.8;p<0.0001),且与钠排泄变化相关(r=0.43;p<0.0001)。
  • 高钠饮食下,帕立骨化醇在1个月治疗期内较安慰剂降低盐诱导的白蛋白尿增加17.8%(95%CI 3.9-32.3;p=0.02);低钠饮食下,帕立骨化醇与安慰剂相比无显著效应(增加4.1%,95%CI -9.3至21.6;p=0.59)。
  • 安慰剂治疗期间,低钠饮食使白蛋白尿降低(p=0.0002),高钠饮食无显著变化,但饮食组间变化差异显著(p=0.0004)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Macroalbuminuria predicts renal and cardiovascular events in patients with type 2 diabetes. We aimed to assess the albuminuria-lowering effects of salt restriction, paricalcitol therapy, or both, in this population. METHODS: In this randomised, double-blind, placebo-controlled, crossover trial, we recruited adult patients with type 2 diabetes from six diabetology outpatient clinics in northern Italy, with 24 h albuminuria of more than 300 mg despite 100 mg per day losartan therapy, blood pressure of less than 140/90 mm Hg, serum creatinine concentration of less than 2 mg/dL, stable renal function on stable renin-angiotensin system inhibitor therapy with a fixed dose of losartan, parathyroid hormone concentration of 20 pg/mL to <110 pg/mL, serum calcium concentration of less than 9·5 mg/dL, and serum phosphate concentration of less than 5 mg/dL, who had been more than 80% compliant with placebo treatment during a 1 month placebo run-in. We allocated patients 1:1 with computer-generated randomisation to an open-label 3 month high-sodium (>200 mEq [4·8 g] per day) or low-sodium (<100 mEq [2·4 g] per day) diet and, within each diet group, to a 1 month double-blind treatment period of oral paricalcitol (2 μg per day) or placebo, followed by 1 month of placebo washout and then a further 1 month double-blind treatment period of paricalcitol or placebo in which patients crossed over to the opposite treatment period. The primary outcome was 24 h albuminuria (median of three consecutive measurements). Analyses were modified intention-to-treat (including all randomly allocated patients who took at least one dose of study drug and had an efficacy measurement after the first treatment period). Patients and investigators were masked to paricalcitol and placebo assignment. Those assessing outcomes were masked to both study drug and diet assignment. This study is registered with ClinicalTrials.gov, number NCT01393808, and the European Union Clinical Trials Register, number 2011-001713-14. FINDINGS: Between Dec 13, 2011, and Feb 17, 2015, we randomly allocated 57 (50%) patients to a low-sodium diet (28 [49%] to paricalcitol then placebo and 29 [51%] to placebo then paricalcitol) and 58 (50%) to a high-sodium diet (29 [50%] to paricalcitol then placebo and 29 [50%] to placebo then paricalcitol). In the low-sodium group (30 mEq of daily sodium intake reduction, equivalent to approximately 1·7-1·8 g per day), 24 h albuminuria was reduced by 36·6% (95% CI 28·5-44·9) from 724 mg (441-1233) at baseline to 481 mg (289-837) at month 3 (p<0·0001), but no significant change occurred in the high-sodium group (from 730 mg [416-1227] to 801 mg [441-1365]; 2·9% [-16·8 to 16·4] increase; p=0·50). Changes between diet groups differed by 32·4% (17·2-48·8; p<0·0001) and correlated with changes in natriuresis (r=0·43; p<0·0001). On the high-sodium diet, paricalcitol reduced the salt-induced albuminuria increase by 17·8% (3·9-32·3) over the month of treatment compared with placebo (p=0·02), whereas on the low-sodium diet, paricalcitol did not have a significant effect versus placebo (increase of 4·1% [-9·3 to 21·6]; p=0·59). During placebo treatment, albuminuria decreased with the low-sodium diet (p=0·0002) and did not significantly change with the high-sodium diet, but changes were significantly different between diet groups (p=0·0004). Treatment was well tolerated and no patients withdrew from the study because of treatment-related effects. 67 adverse events occurred in 52 (45%) patients during paricalcitol treatment and 44 events occurred in 36 (31%) patients during placebo treatment. During paricalcitol therapy, 14 cases of hypercalciuria, six cases of hypercalcaemia, and five cases of hyperphosphataemia were reported in one patient each, all of which were possibly treatment related. One case of hypercalciuria was reported in one patient during the placebo treatment period. One stroke and one coronary event occurred during paricalcitol therapy. No patients died during the study. INTERPRETATION: In patients with macroalbuminuria and type 2 diabetes, moderate salt restriction enhances the antialbuminuric effect of losartan, an effect that could be nephroprotective and cardioprotective in the long term. The finding that paricalcitol prevents a sodium-induced increase in albuminuria provides support for trials to test the long-term risk-benefit profile of paricalcitol add-on therapy in patients with type 2 diabetes and macroalbuminuria refractory to dietary salt restriction, including patients refractory to even moderate salt restriction. FUNDING: AbbVie.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Parvanova A, Trillini M, Podestà MA, et al. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. Lancet Diabetes Endocrinol. 2017. PMID: 29104158. doi:10.1016/S2213-8587(17)30359-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。